MX360710B - Antagonistas de il17c para el tratamiento de trastornos inflamatorios. - Google Patents

Antagonistas de il17c para el tratamiento de trastornos inflamatorios.

Info

Publication number
MX360710B
MX360710B MX2014004662A MX2014004662A MX360710B MX 360710 B MX360710 B MX 360710B MX 2014004662 A MX2014004662 A MX 2014004662A MX 2014004662 A MX2014004662 A MX 2014004662A MX 360710 B MX360710 B MX 360710B
Authority
MX
Mexico
Prior art keywords
il17c
treatment
inflammatory disorders
inflammatory disorder
antagonists
Prior art date
Application number
MX2014004662A
Other languages
English (en)
Other versions
MX2014004662A (es
Inventor
Bültmann Andreas
Mühlbacher Robert
Garcia Teresa
Christophe Xavier Brys Reginald
Nelles Luc
Conrath Katja
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2014004662A publication Critical patent/MX2014004662A/es
Publication of MX360710B publication Critical patent/MX360710B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un anticuerpo o fragmento de anticuerpo aislado específico para IL17C para su uso en el tratamiento de un trastorno inflamatorio, en donde dicho trastorno inflamatorio es inflamación pulmonar, artritis reumatoidea y/o COP (enfermedad pulmonar obstructiva crónica) en donde IL17C consiste en aminoácidos de la SEQ ID NO. 181, y en donde el anticuerpo bloquea la unión de IL17C a IL17RE.
MX2014004662A 2011-10-19 2012-10-19 Antagonistas de il17c para el tratamiento de trastornos inflamatorios. MX360710B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548744P 2011-10-19 2011-10-19
EP11185763 2011-10-19
PCT/EP2012/070736 WO2013057241A1 (en) 2011-10-19 2012-10-19 Antagonists of il17c for the treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
MX2014004662A MX2014004662A (es) 2015-06-02
MX360710B true MX360710B (es) 2018-11-14

Family

ID=48140378

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004662A MX360710B (es) 2011-10-19 2012-10-19 Antagonistas de il17c para el tratamiento de trastornos inflamatorios.

Country Status (22)

Country Link
US (2) US20140243506A1 (es)
EP (2) EP2768859B1 (es)
JP (1) JP2014530836A (es)
CN (1) CN103974976A (es)
AU (1) AU2012324895B2 (es)
CA (1) CA2852145C (es)
CY (1) CY1120219T1 (es)
DK (1) DK2768859T3 (es)
ES (1) ES2669984T3 (es)
HR (1) HRP20180776T1 (es)
HU (1) HUE037087T2 (es)
LT (1) LT2768859T (es)
ME (1) ME03073B (es)
MX (1) MX360710B (es)
PL (1) PL2768859T3 (es)
PT (1) PT2768859T (es)
RS (1) RS57209B1 (es)
SG (1) SG11201401202YA (es)
SI (1) SI2768859T1 (es)
SM (1) SMT201800273T1 (es)
TR (1) TR201807056T4 (es)
WO (1) WO2013057241A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2626437A3 (en) 2008-05-14 2013-12-11 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
WO2012061129A1 (en) * 2010-10-25 2012-05-10 Genentech, Inc Treatment of gastrointestinal inflammation and psoriasis a
WO2019217478A1 (en) * 2018-05-09 2019-11-14 Dermtech, Inc. Novel gene classifiers and uses thereof in autoimmune diseases
RU2017122172A (ru) * 2014-12-15 2019-01-17 МорфоСис АГ Антитела к IL-17C
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
HK1257289A1 (zh) * 2015-10-05 2019-10-18 Morphosys Ag 治疗和/或预防特应性皮炎的il-17c拮抗剂
MA43088B1 (fr) * 2016-02-19 2020-10-28 Morphosys Ag Anticorps anti-il-17c
AU2017259966A1 (en) * 2016-05-03 2018-11-22 The Scripps Research Institute TrkB agonist antibodies for treating neurodegenerative disorders
EP3688031A1 (en) 2017-09-25 2020-08-05 MorphoSys AG Treatment of atopic dermatitis
EP3752645A4 (en) 2018-02-14 2022-04-13 Dermtech, Inc. Novel gene classifiers and uses thereof in non-melanoma skin cancers
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
JP2022524641A (ja) 2019-03-26 2022-05-09 ダームテック，インク． 皮膚癌における新規な遺伝子分類子とその使用
WO2021137305A1 (ko) * 2019-12-30 2021-07-08 경상대학교병원 박테리아 감염증 예방 또는 치료용 약학 조성물
CN112795637A (zh) * 2021-01-08 2021-05-14 孙洪臣 靶向il-17c的抑制剂在治疗炎症相关慢性肾脏疾病中的用途
WO2022204375A1 (en) * 2021-03-25 2022-09-29 The Regents Of The University Of Michigan Compositions and methods for detecting, preventing, and treating disturbed microbiota-immune homeostasis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
PT1076703E (pt) 1998-05-15 2007-10-10 Genentech Inc ''utilizações terapêuticas de polipéptido homólogos de il-17''
EP1144607B1 (en) 1999-07-20 2008-12-17 MorphoSys AG Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
EP1240325B1 (en) * 1999-12-23 2009-09-30 Genentech, Inc. Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
US20040197306A1 (en) * 2000-05-24 2004-10-07 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
JP2005512044A (ja) 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 結合特性に基づく抗体分類
AU2005295421A1 (en) * 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble Zcytor21, anti-Zcytor21 antibodies and binding partners and methods of using in inflammation
EP1931708A1 (en) * 2005-10-18 2008-06-18 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
CA2666842A1 (en) * 2006-10-18 2008-04-24 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
EP2217268B1 (en) * 2007-12-07 2016-05-04 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
WO2009132821A1 (en) * 2008-04-28 2009-11-05 Giuliani International Limited Interleukin (il-21) binding proteins and methods of making and using same
US20130064788A1 (en) * 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
WO2012061129A1 (en) * 2010-10-25 2012-05-10 Genentech, Inc Treatment of gastrointestinal inflammation and psoriasis a
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology

Also Published As

Publication number Publication date
HRP20180776T1 (hr) 2018-08-10
WO2013057241A1 (en) 2013-04-25
US20140243506A1 (en) 2014-08-28
US20190062422A1 (en) 2019-02-28
EP2768859B1 (en) 2018-02-21
SI2768859T1 (en) 2018-06-29
TR201807056T4 (tr) 2018-06-21
ME03073B (me) 2019-01-20
MX2014004662A (es) 2015-06-02
EP2768859A1 (en) 2014-08-27
SMT201800273T1 (it) 2018-07-17
NZ623289A (en) 2015-12-24
CA2852145A1 (en) 2013-04-25
PT2768859T (pt) 2018-05-23
LT2768859T (lt) 2018-06-11
CN103974976A (zh) 2014-08-06
RS57209B1 (sr) 2018-07-31
US10815297B2 (en) 2020-10-27
AU2012324895A1 (en) 2014-04-17
HUE037087T2 (hu) 2018-08-28
CA2852145C (en) 2021-01-12
DK2768859T3 (en) 2018-06-06
EP3360897A1 (en) 2018-08-15
JP2014530836A (ja) 2014-11-20
SG11201401202YA (en) 2014-06-27
PL2768859T3 (pl) 2018-07-31
CY1120219T1 (el) 2018-12-12
ES2669984T3 (es) 2018-05-29
AU2012324895B2 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
MX360710B (es) Antagonistas de il17c para el tratamiento de trastornos inflamatorios.
AR095193A1 (es) Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios
CL2013001213A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de este para tratar artritis reumatoide.
CL2014000699A1 (es) Proteina de union al antigeno cd27l; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; composicion que la comprende; su uso para tratar cancer, trastornos autoinmunitarios o inflamatorios; y metodo para elaborar un conjugado anticuerpo cd27l-farmaco.
MX388710B (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su uso.
CL2011002831A1 (es) Anticuerpo humanizado especifico de la forma protofibrilar del peptido a-beta; uso de dicho anticuerpo para tratar transtornos neurodegenerativos; composicion farmaceutica; celula que produce dichos anticuerpos; y procedimientos de preparacion de dicho anticuerpo.
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
UA110358C2 (en) Molecules of antibody binding il-17a and il-17f
CL2014000134A1 (es) Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada; uso de dicha proteina para tratar diferentes tipos de artritis y psoriasis, entre otras enfermedades; celula hospedera que codifica dicha proteina.
AR082017A1 (es) Anticuerpos anti-axl (receptor de tirosina quinasas) y metodos de uso
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
CL2014001054A1 (es) Proteina de enlace que se une al factor de necrosis tumoral alfa (tnf-alfa); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; su uso para tratar un trastorno asociado a tnf-alfa; y metodo para determinar la presencia de tnf-alfa en una muestra.
NZ599737A (en) Il-17a antagonists
EA201592006A1 (ru) Новые биспецифические связывающие молекулы с противоопухолевой активностью
AR072749A1 (es) Anticuerpos contra receptor del factor de la necrosis tumoral (baffr) y composiciones farmaceuticas
MX374708B (es) Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenarativos.
EA201300876A1 (ru) Мутантная целлобиогидролаза
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
ECSP11011429A (es) Tratamiento de trastornos resistentes a insulina
BR112013024923A2 (pt) novo anticorpo receptor de il-23 anti-humano
WO2015198217A3 (en) Antibodies specific for il-17a fused to hyaluronan binding peptide tags
BR112012026545A2 (pt) composições e métodos para tratar exacerbação de copd
ES2581488T3 (es) Nuevos métodos para el tratamiento de enfermedades inflamatorias
ES2669528T3 (es) Receptor Tie2 específico de angiopoyetina-2
EA201491957A1 (ru) Антитела к ccl2 для лечения склеродермии

Legal Events

Date Code Title Description
FG Grant or registration